Who are Alethia Biotherapeutics Inc.'s investors?

Alethia Biotherapeutics Inc.'s investors include BDC Fund Investments (Fund-of-Funds), BDC Venture Capital, BDC Capital Corporation, GO Capital.

Alethia Biotherapeutics Inc.

Founded 2002 · 12 employees on LinkedIn · 6 known investors

Find your way into Alethia Biotherapeutics Inc.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Alethia Biotherapeutics Inc. team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Alethia Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments that target tumor resistance by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment. Its lead asset, sotevtamab, is a monoclonal antibody intended to be combined with standard therapies across multiple cancer indications.

Biotech Healthtech

Investors · 6

BDC Fund Investments (Fund-of-Funds)listed by BDC Fund Investments (Fund-of-Funds)Montréal

How we know: BDC Fund Investments (Fund-of-Funds)'s portfolio page · Not right? Tell us

BDC Venture Capitallisted by BDC Venture CapitalMontreal · $365K – $25.6M

How we know: funding news · biospace.com · Not right? Tell us

BDC Capital CorporationreportedWakefield

How we know: funding news · Not right? Tell us

GO CapitalreportedSaint Jacques de la Lande · $162K – $2.2M

How we know: funding news · biospace.com · Not right? Tell us

Also in the syndicate · 2

AgeChem Venture FundleadEpicentre Technologies Corporation

Funding

SEC filings, press & company announcements

Undisclosed amountSeries ASep 2010
AgeChem Venture Fund (lead), BDC Venture Capital (lead), Epicentre Technologies Corporation, GO Capital
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Alethia BioTherapeutics, Inc. Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline - BioSpacebiospace.com · Sep 2010

Frequently asked questions

What does Alethia Biotherapeutics Inc. do?: Alethia Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments that target tumor resistance by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment. Its lead asset, sotevtamab, is a monoclonal antibody intended to be combined with standard therapies across multiple cancer indications.
Who are Alethia Biotherapeutics Inc.'s investors?: Alethia Biotherapeutics Inc.'s investors include BDC Fund Investments (Fund-of-Funds), BDC Venture Capital, BDC Capital Corporation, GO Capital.